Oral BMS-354825 rescues Gleevec-resistant CML

被引：0
|
作者：
不详
机构：
来源：
CANCER BIOLOGY & THERAPY | 2004年 / 3卷 / 08期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
下载
收藏
页码：700 / 700
页数：1
相关论文
共 50 条
  • [1] Two new agents effective in Gleevec-resistant CML
    不详
    CANCER BIOLOGY & THERAPY, 2004, 3 (12) : 1198 - 1199
  • [2] Dasatinib on fast track for approval by FDA for gleevec-resistant CML
    不详
    CANCER BIOLOGY & THERAPY, 2006, 5 (07) : 709 - 710
  • [3] Possible role of catalase activity as a biomarker for Gleevec-resistant CML patients
    Luque, DG
    Ferreira, ACDS
    Kwee, JK
    Coelho, AM
    Dobbin, J
    Maia, RC
    FREE RADICAL BIOLOGY AND MEDICINE, 2004, 37 : S172 - S172
  • [4] Dasatinib (BMS-354825) overcomes multiple mechanisms of imatinib resistance in chronic myeloid leukemia (CML)
    Lee, FY
    Wen, ML
    Bhide, R
    Camuso, A
    Castenada, S
    Fager, K
    Flefleh, C
    Inigo, I
    Kan, D
    Luo, R
    Mcglinchey, K
    Smykla, R
    Wild, R
    Borzilleri, R
    Lombardo, L
    BLOOD, 2005, 106 (11) : 564A - 565A
  • [5] Dynamics of molecular response to dasatinib (BMS-354825) in patients (pts) with chronic myelogenous leukemia (CML) resistant or intolerant to imatinib.
    Quintas-Cardama, A.
    Kantarjian, H.
    Jones, D.
    Talpaz, M.
    Jabbour, E.
    O'Brien, S.
    Luthra, R.
    Wierda, W.
    Nicaise, C.
    Cortes, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 343S - 343S
  • [6] Nilotinib appears beneficial in phase I study for patients with Gleevec-resistant CML
    不详
    CANCER BIOLOGY & THERAPY, 2006, 5 (07) : 711 - 711
  • [7] BMS-354825: a novel drug with potential for the treatment of imatinib-resistant chronic myeloid leukaemia
    Doggrell, SA
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2005, 14 (01) : 89 - 91
  • [8] AMN107, a designed Bcr-Abl inhibitor effective in Gleevec-resistant CML
    不详
    CANCER BIOLOGY & THERAPY, 2005, 4 (03) : I - I
  • [9] Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction
    Copland, Mhairi
    Hamilton, Ashley
    EIrick, Lucy J.
    Baird, Janet W.
    Allan, Elaine K.
    Jordanides, Niove
    Barow, Martin
    Mountford, Joanne C.
    Holyoake, Tessa L.
    BLOOD, 2006, 107 (11) : 4532 - 4539
  • [10] A phase I study of BMS-354825 in patients with imatinib-resistant and intolerant chronic phase chronic myeloid leukemia (CML): Results from CA180002.
    Talpaz, M
    Kantarjian, HM
    Paquette, R
    Shah, N
    Cortes, J
    Nicoll, J
    Bai, SA
    Huang, F
    Decillis, AP
    Sawyers, CL
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 564S - 564S
12345